157 related articles for article (PubMed ID: 24045668)
1. Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma.
Gilabert M; Provansal M; Cappiello M; Walz Y; Salem N; Tarpin C; Brunelle S; Thomassin J; Gravis G
Br J Cancer; 2013 Oct; 109(7):1750-4. PubMed ID: 24045668
[TBL] [Abstract][Full Text] [Related]
2. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.
Noda S; Otsuji T; Baba M; Yoshida T; Kageyama S; Okamoto K; Okada Y; Kawauchi A; Onishi H; Hira D; Morita SY; Terada T
Clin Genitourin Cancer; 2015 Aug; 13(4):350-358. PubMed ID: 25701374
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
Michels J; Lassau N; Gross-Goupil M; Massard C; Mejean A; Escudier B
Invest New Drugs; 2010 Oct; 28(5):690-3. PubMed ID: 19547920
[TBL] [Abstract][Full Text] [Related]
5. Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
Molina AM; Jia X; Feldman DR; Hsieh JJ; Ginsberg MS; Velasco S; Patil S; Motzer RJ
Clin Genitourin Cancer; 2013 Sep; 11(3):297-302. PubMed ID: 23707221
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Ravaud A; Oudard S; De Fromont M; Chevreau C; Gravis G; Zanetta S; Theodore C; Jimenez M; Sevin E; Laguerre B; Rolland F; Ouali M; Culine S; Escudier B
Ann Oncol; 2015 Jun; 26(6):1123-1128. PubMed ID: 25802238
[TBL] [Abstract][Full Text] [Related]
7. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
[TBL] [Abstract][Full Text] [Related]
8. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
9. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma.
Tomita Y; Shinohara N; Yuasa T; Fujimoto H; Niwakawa M; Mugiya S; Miki T; Uemura H; Nonomura N; Takahashi M; Hasegawa Y; Agata N; Houk B; Naito S; Akaza H
Jpn J Clin Oncol; 2010 Dec; 40(12):1166-72. PubMed ID: 20713418
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib as adjuvant therapy for renal cell carcinoma.
Baker H
Lancet Oncol; 2016 Nov; 17(11):e485. PubMed ID: 27773485
[No Abstract] [Full Text] [Related]
11. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
12. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Rixe O; Oudard S; Negrier S; Szczylik C; Kim ST; Chen I; Bycott PW; Baum CM; Figlin RA
N Engl J Med; 2007 Jan; 356(2):115-24. PubMed ID: 17215529
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
15. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
16. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 May; 94(2):238-50. PubMed ID: 25638704
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
19. Fatal liver failure in a patient treated with sunitinib for renal cell carcinoma.
Mermershtain W; Lazarev I; Shani-Shrem N; Ariad S
Clin Genitourin Cancer; 2013 Mar; 11(1):70-2. PubMed ID: 23063577
[No Abstract] [Full Text] [Related]
20. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
